allogeneic bone marrow-derived mesenchymal stem cells (Mayo Clinic)

This investigational cell-based therapy, developed by the Mayo Clinic, consists of allogeneic bone marrow-derived mesenchymal stem cells (MSCs) for the treatment of advanced chronic obstructive pulmonary disease (COPD). The MSCs are cultured and expanded at Mayo Clinic's own good manufacturing practice (GMP) facility and are administered intravenously to patients with severe or very severe COPD who have a history of at least one acute exacerbation in the previous year. The therapeutic mechanism involves the cells' immunomodulatory effects, antimicrobial properties, and their capacity to promote tissue repair in damaged lung tissue. Following intravenous administration, the cells preferentially home to the lungs to exert their effects. A Phase 1 dose-escalation trial (NCT04047810) has been conducted to evaluate the safety and feasibility of this approach, with potential for expansion into Phase 2 studies.

Other names

mesenchymal stem cellsMSCs